Just about the hottest thing in longevity science right now is partial reprogramming - using Yamanaka factors to rewind the biological clock in our cells. Billion-dollar giants like Altos, Retro and New Limit are betting on it.

But in this episode a far smaller player, Shift Bioscience, argues that the field may be looking in the wrong place. CEO Daniel Ives explains how his team used AI-powered virtual cells to uncover a single gene that seems to match OSK-level rejuvenation without the tumor risk that haunts classical reprogramming - and why their just-released data could change the game for aging research.

🔍 In this conversation

✅ Daniel’s journey from mitochondrial PhD work to founding Shift Bioscience.

✅ Why Yamanaka-factor–based partial reprogramming excites the field and why it’s inherently risky.

✅ Epigenetic clocks 101 — Horvath, single-cell versions, and what they really measure.

✅ Building AI “virtual cells” (transformers / GNNs) to run millions of in-silico experiments.

✅ Discovery of new rejuvenation factor sets - including SB000, a lone gene that rejuvenates without inducing pluripotency.

✅ Early wet-lab validation across fibroblasts & keratinocytes; next-step mouse studies already under way.

✅ How inhibition targets (not just over-expression) could slash timelines from 15 years to ~5 years.

✅ Mapping a “risk landscape” of age-linked diseases and why fibrosis may be the fastest clinical entry point.

✅ Funding Shift: from personal redundancy money to a $16 M seed and the next raise.

✅ Timelines, escape-velocity hopes, and where cryonics still fits.

✅ What Daniel would ask Jeff Bezos, and why the pharma ecosystem needs to “plug in” now.

🚀 Special offer for our LEVITY audience: Join Vitalism today and receive a 30% discount on your membership using the code LEVITY at checkout. https://www.vitalism.io/membership

🚀 Show notes for this episode will be available soon after this airs. Sign up for the LEVITY newsletter to get them straight to your inbox: reachlevity.com

🚀 LEVITY is co-hosted by Patrick Linden, philosopher and author, and Peter Ottsjö, journalist and author.

CHAPTERS

00:00 Introduction to Daniel Ives

05:34 The Evolution of Shift's Focus

13:25 Understanding Aging Clocks

19:28 Commercial Clocks is ”Mostly Entertainment”

21:03 A Pivotal Meeting with Steve Horvath

24:35 A Brief Crash Course in Yamanaka Factors

28:16 Finding Something Better Than Yamanaka Factors

33:20 The Origin Story For This Approach

36:50 What Does Shift’s New Results Show?

37:33 Defining the Virtual Cell in This Context

44:22 The Gene is Called SB000

46:45 “This Could be Hugely Important”

01:01:44 Speeding up Drug Development with AI

01:11:12 What do Investors Say?

01:17:15 What Daniel Hope Will Happen Next

01:19:34 What Would Daniel Ask of Jeff Bezos?

01:27:00 Why is the company called Shift?

01:32:55 The Pride Day for Closeted Aging Biologists

01:42:28 How Should We Think About Cryonics?

Hosted on Acast. See acast.com/privacy for more information.